title: Patient perspective on zanamivir in the treatment of influenza.
abstract: Placebo-controlled clinical studies have shown zanamivir to be an effective treatment of influenza A and influenza B illness. This survey, conducted in France, was done to evaluate patients' perception of zanamivir in clinical practice. Between January and mid-April 2000, 271 retail pharmacists gave questionnaires to patients with a prescription for zanamivir to be completed on a voluntary basis. A total of 514 patients returned completed questionnaires, of whom 97 (19%) were considered at high risk of developing influenza complications. Fifty-one (10%) patients, mainly those over 65 years, were vaccinated against influenza. Fever or feverishness was reported by 93% of patients, and cough, myalgia and headache by 72%. Most (58%) patients consulted their doctor within 24 hours of the onset of symptoms, and 96% within 48 hours. Eighty-five per cent of patients overall and 82% of high-risk individuals (82/97) reported being satisfied with their zanamivir treatment. Treatment compliance was high with 75% of patients completing the whole course of treatment. Symptom relief was reported by 45% of patients within 24 hours and by 74% of patients within 48 hours; 66% of patients resumed normal activities within 72 hours. These results suggest that patient satisfaction is high and compliance with zanamivir is highly satisfactory. In addition, the use of zanamivir was reported to be associated with rapidsymptom relief and return to normal activity
authors.affiliation: Infectious and Tropical Diseases Department, Pitié Salpétrière Hospital, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Bricaire
authors.forename: J M
authors.initials: JM
authors.lastname: Cohen
authors.forename: M
authors.initials: M
authors.lastname: Jacquet
authors.forename: I
authors.initials: I
authors.lastname: Boucot
authors.forename: M
authors.initials: M
authors.lastname: Nicolas
mesh_terms: D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005602:France; D006146:Guanidines; D006801:Humans; D009980:Influenza A virus; D009981:Influenza B virus; D007251:Influenza, Human / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D017060:Patient Satisfaction; D011714:Pyrans; D012794:Sialic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome; D053243:Zanamivir
chemical_list: D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053243:Zanamivir